232 related articles for article (PubMed ID: 19638586)
41. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma.
Van Maerken T; Speleman F; Vermeulen J; Lambertz I; De Clercq S; De Smet E; Yigit N; Coppens V; Philippé J; De Paepe A; Marine JC; Vandesompele J
Cancer Res; 2006 Oct; 66(19):9646-55. PubMed ID: 17018622
[TBL] [Abstract][Full Text] [Related]
42. Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors.
Li Y; Saini P; Sriraman A; Dobbelstein M
Oncotarget; 2015 Oct; 6(32):32339-52. PubMed ID: 26431163
[TBL] [Abstract][Full Text] [Related]
43. The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276.
Li R; Zatloukalova P; Muller P; Gil-Mir M; Kote S; Wilkinson S; Kemp AJ; Hernychova L; Wang Y; Ball KL; Tao K; Hupp T; Vojtesek B
Cell Mol Biol Lett; 2020; 25():41. PubMed ID: 32874188
[TBL] [Abstract][Full Text] [Related]
44. p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a.
Duan L; Perez RE; Chen L; Blatter LA; Maki CG
J Mol Cell Biol; 2018 Aug; 10(4):331-340. PubMed ID: 29190376
[TBL] [Abstract][Full Text] [Related]
45. Podocyte loss involves MDM2-driven mitotic catastrophe.
Mulay SR; Thomasova D; Ryu M; Kulkarni OP; Migliorini A; Bruns H; Gröbmayr R; Lazzeri E; Lasagni L; Liapis H; Romagnani P; Anders HJ
J Pathol; 2013 Jul; 230(3):322-35. PubMed ID: 23749457
[TBL] [Abstract][Full Text] [Related]
46. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.
Patton JT; Mayo LD; Singhi AD; Gudkov AV; Stark GR; Jackson MW
Cancer Res; 2006 Mar; 66(6):3169-76. PubMed ID: 16540668
[TBL] [Abstract][Full Text] [Related]
47. Antiangiogenic activity of the MDM2 antagonist nutlin-3.
Secchiero P; Corallini F; Gonelli A; Dell'Eva R; Vitale M; Capitani S; Albini A; Zauli G
Circ Res; 2007 Jan; 100(1):61-9. PubMed ID: 17138942
[TBL] [Abstract][Full Text] [Related]
48. Nutlin-3 affects expression and function of retinoblastoma protein: role of retinoblastoma protein in cellular response to nutlin-3.
Du W; Wu J; Walsh EM; Zhang Y; Chen CY; Xiao ZX
J Biol Chem; 2009 Sep; 284(39):26315-21. PubMed ID: 19648117
[TBL] [Abstract][Full Text] [Related]
49. Dual-channel surface plasmon resonance monitoring of intracellular levels of the p53-MDM2 complex and caspase-3 induced by MDM2 antagonist Nutlin-3.
Wu L; Hu Y; He Y; Xia Y; Lu H; Cao Z; Yi X; Wang J
Analyst; 2019 Jul; 144(13):3959-3966. PubMed ID: 31134974
[TBL] [Abstract][Full Text] [Related]
50. Targeting MDM2 by the small molecule RITA: towards the development of new multi-target drugs against cancer.
Espinoza-Fonseca LM
Theor Biol Med Model; 2005 Sep; 2():38. PubMed ID: 16174299
[TBL] [Abstract][Full Text] [Related]
51. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT
Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686
[TBL] [Abstract][Full Text] [Related]
52. Senescence induction in renal carcinoma cells by Nutlin-3: a potential therapeutic strategy based on MDM2 antagonism.
Polański R; Noon AP; Blaydes J; Phillips A; Rubbi CP; Parsons K; Vlatković N; Boyd MT
Cancer Lett; 2014 Oct; 353(2):211-9. PubMed ID: 25067787
[TBL] [Abstract][Full Text] [Related]
53. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.
Burmakin M; Shi Y; Hedström E; Kogner P; Selivanova G
Clin Cancer Res; 2013 Sep; 19(18):5092-103. PubMed ID: 23864164
[TBL] [Abstract][Full Text] [Related]
54. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin.
Efeyan A; Ortega-Molina A; Velasco-Miguel S; Herranz D; Vassilev LT; Serrano M
Cancer Res; 2007 Aug; 67(15):7350-7. PubMed ID: 17671205
[TBL] [Abstract][Full Text] [Related]
55. The pharmacodynamics of the p53-Mdm2 targeting drug Nutlin: the role of gene-switching noise.
Puszynski K; Gandolfi A; d'Onofrio A
PLoS Comput Biol; 2014 Dec; 10(12):e1003991. PubMed ID: 25504419
[TBL] [Abstract][Full Text] [Related]
56. Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes.
Arva NC; Talbott KE; Okoro DR; Brekman A; Qiu WG; Bargonetti J
Ethn Dis; 2008; 18(2 Suppl 2):S2-1-8. PubMed ID: 18646312
[TBL] [Abstract][Full Text] [Related]
57. MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response.
Mancini F; Pieroni L; Monteleone V; Lucà R; Fici L; Luca E; Urbani A; Xiong S; Soddu S; Masetti R; Lozano G; Pontecorvi A; Moretti F
Oncogene; 2016 Jan; 35(2):228-40. PubMed ID: 25961923
[TBL] [Abstract][Full Text] [Related]
58. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.
Kojima K; Konopleva M; Samudio IJ; Shikami M; Cabreira-Hansen M; McQueen T; Ruvolo V; Tsao T; Zeng Z; Vassilev LT; Andreeff M
Blood; 2005 Nov; 106(9):3150-9. PubMed ID: 16014563
[TBL] [Abstract][Full Text] [Related]
59. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.
Di Marzo D; Forte IM; Indovina P; Di Gennaro E; Rizzo V; Giorgi F; Mattioli E; Iannuzzi CA; Budillon A; Giordano A; Pentimalli F
Cell Cycle; 2014; 13(4):652-65. PubMed ID: 24345738
[TBL] [Abstract][Full Text] [Related]
60. Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells.
Veschi V; Petroni M; Cardinali B; Dominici C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Giannini G
PLoS One; 2012; 7(11):e49139. PubMed ID: 23152863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
